Regorafenib,835621-08-4

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Regorafenib mesylate

CAS No. : 835621-08-4

MCE 国际站：Regorafenib mesylate

产品活性：Regorafenib (BAY 73-4506) mesylate 是一种口服有效的多靶点受体酪氨酸激酶 (tyrosine kinase) 抑制剂，抑制 VEGFR1/2/3，PDGFRβ，Kit，RET 和 Raf-1 的 IC₅₀ 分别为 13/4.2/46，22，7，1.5 和 2.5 nM。Regorafenib mesylate 显示出非常强的抗肿瘤和抗血管生成活性。

研究领域：Protein Tyrosine Kinase/RTK  |  MAPK/ERK Pathway  |  Autophagy

作用靶点：VEGFR  |  PDGFR  |  RET  |  Raf  |  c-Kit  |  FGFR  |  Autophagy  |  Tie

In Vitro: Regorafenib mesylate (0-10 μM, 96 h) shows anti-proliferation activity in GIST 882, Thyroid TT, MDA-MB-231, HepG2, A375 and SW620 cells.
Regorafenib mesylate (0-3000 nM, 30 min) inhibits the autophosphorylation of VEGFR2, TIE2 and PDGFR-β, and inhibits FGFR and pERK1/2.
Regorafenib mesylate causes a concentration-dependent decrease in Hep3B cell growth, with an IC₅₀ of 5 μM. Regorafenib subsequently increases the levels of phospho-c-Jun, a JNK target, but not total c-Jun in Hep3B cells.

In Vivo: Regorafenib mesylate (10 mg/kg, Orally, single dose or daily for 4 days) inhibits tumor vasculature and tumor growth in a rat GS9L glioblastoma model.
Regorafenib mesylate (0-100 mg/kg, Orally, qd × 9) exhibits antitumorigenic and antiangiogenic effects in the Colo-205, MDA-MB-231 and 786-O model.

相关产品：Sorafenib  |  Lenvatinib  |  Pexidartinib  |  Dabrafenib  |  Vemurafenib  |  Sunitinib  |  Regorafenib  |  Nintedanib  |  Bevacizumab  |  Imatinib  |  Semaxinib  |  Cabozantinib  |  Doramapimod  |  Ponatinib  |  Erdafitinib  |  Infigratinib  |  Encorafenib  |  Axitinib  |  Midostaurin  |  Pemigatinib  |  Chloramphenicol  |  Pazopanib  |  Futibatinib  |  Fexagratinib  |  PD173074  |  Pralsetinib  |  Selpercatinib  |  Heparan Sulfate

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds